revenu vs our/street core growth
organ basi ex-abaxi fx headwind beat led
companion anim strength primarili innov dermatolog portfolio
simparica livestock result weak due favor
mix price increas opex control margin came well-ahead gm
opm adj ep ahead estim although
non-op item tax rate incom first look detail
plenti company-specif issu livestock busi
although top-lin result larg expect slew surpris
print livestock sale constant currenc cc vs expect low-
single-digit growth approxim swing due company-specif
issu divest agribusi japan slowdown brazil follow
aggress price distributor destock us follow bulk
purchas ahead price increas notabl factor
result hit african swine fever asf outbreak china soft
quarter abaxi yoy follow prior year distributor stock
work move piec believ like fade/revers
move year except asf addit key driver
companion anim busi derm portfolio simparica revolut continu
well apoquel approv china open anoth major market
thought major chang outlook beyond fx
see quarter perfect exampl see zoeti core hold
divers portfolio multipl potenti sourc upsid allow compani off-set
mani individu pressur point still deliv solid result midst challeng
market condit management also reiter guid except higher fx
headwind tweak model softer livestock throughout year stronger
companion less abaxi contribut estimate chang larg due fx
reiter buy rate rais po po price-to-earnings vs previous
net dbt
livestock stumbl puppi
rescu
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
zoeti global leader discoveri
develop manufactur
commerci anim health medicin
vaccin product companion
anim market well-diversifi portfolio
product line span eight core
speci five therapeut categori directli
market countri industri
believ zoeti benefit rise
demand companion product anim
health product particularli emerg market
new product product line extens
expand ancillari servic offer greater
oper work capit effici
opportunist invest acquisit and/or
partnership supplement growth
po base approxim ep estim back
dcf assum wacc termin growth rate in-lin
current multipl albeit slightli higher recent valuat trend
believ justifi given upsid new product launch increment capit
deploy margin expans opportun defens natur
downsid risk price object competit select market weaker demand
anim health product regulatori issu macroeconom condit currenc risk
headwind relat regul antibiot use anim feed addit
michael ryskin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
